Venture Life Group PLC Issue of Equity (5949I)
14 Dicembre 2020 - 03:07PM
UK Regulatory
TIDMVLG
RNS Number : 5949I
Venture Life Group PLC
14 December 2020
14 December 2020
Venture Life Group plc
("Venture Life" or the "Company")
Exercise of Share Options & Voting Rights
Venture Life (AIM: VLG), a leading developer, manufacturer and
distributer of consumer self-care products, announces that is has
issued 21,000 ordinary shares of 0.3 pence each in the capital of
the Company ("Ordinary Shares") in accordance with an exercise of
employee share options.
Application will be made to the London Stock Exchange for the
21,000 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 21 December
2020.
Following Admission, the total number of Ordinary Shares in
issue will be 125,831,530 and the total number of voting rights
will therefore be 125,831,530. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900
Stephen Keys / Camilla Hume (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
N+1 Singer (Joint Broker)
Shaun Dobson / Carlo Spingardi (Corporate Finance) +44 (0) 20 7496 3000
Jonathan Dighe (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFFMFLLESSESE
(END) Dow Jones Newswires
December 14, 2020 09:07 ET (14:07 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2023 a Mar 2024